Nicole Déglon

Nicole Déglon is an Associate Professor at the University of Lausanne (UNIL), Faculty of Biology and Medicine, affiliated with the Department of Clinical Neurosciences at CHUV. She leads the Cellular and Molecular Neurotherapies Laboratory (LNCM) and serves as Head of the Center for Research in Neuroscience (CRN), fostering collaboration between clinicians and basic scientists in Lausanne’s vibrant research ecosystem involving UNIL, CHUV, and EPFL.

Her research is centered on developing innovative molecular therapies for neurodegenerative disorders, with a strong focus on Huntington’s disease. She employs viral gene transfer technologies to deliver therapeutic agents such as neurotrophic factors (e.g., CNTF) and has pioneered approaches using small interfering RNAs to silence the mutant huntingtin gene. Her lab also investigates disease mechanisms, including tau protein spreading in tauopathies and mitochondrial dysfunction in early Alzheimer’s disease, leveraging cell-type-specific transgene expression in the central nervous system.

Although specific publications are not listed in the provided text, her work is well-aligned with translational neuroscience, having contributed to clinical trials and preclinical development at institutions such as CEA and CHUV. Her research integrates gene editing, viral vector engineering, and neuropathological modeling to advance novel treatment strategies for currently incurable neurological conditions.

• No scientific awards are mentioned in the provided text.

Dr. Déglon has supervised research teams and mentored scientists, though no named students are listed. She has secured significant research roles and leadership positions, indicating success in obtaining research funding and institutional support. Her career trajectory includes key appointments at the Salk Institute, EPFL, and the French Atomic Energy Commission (CEA), demonstrating sustained research excellence and leadership in neuroscience.

She directs the Cellular and Molecular Neurotherapies Laboratory at CHUV, which she founded in 2011, and leads the Center for Research in Neuroscience. Her team focuses on gene therapy platforms, preclinical modeling of neurodegenerative diseases, and the development of targeted molecular interventions for the brain.